The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells
Open accessAbstract
Background: BRAF inhibitors, such as vemurafenib, have shown efficacy in BRAF -mutant melanoma treatment but acquired-resistance invariably develops. Unveiling the potential vulnerabilities associated with vemurafenib resistance could provide rational strategies for combinatorial treatment. Methods: This work investigates the metabolic characteristics and vulnerabilities of acquired resistance to vemurafenib in three generated BRAF -mutant human melanoma cell clones, analysing metabolic profiles, gene and protein expression in baseline and nutrient withdrawal conditions. Preclinical findings are correlated with gene expression analysis from publicly available clinical datasets. Results: Two vemurafenib-resistant clones showed dependency on lipid metabolism and increased prostaglandin E2 synthesis and were more responsive to vemurafenib under EGFR inhibition, potentially implicating inflammatory lipid and EGFR signalling in ERK reactivation and vemurafenib resistance. The third resistant clone showed higher pyruvate-carboxylase (PC) activity indicating increased anaplerotic mitochondrial metabolism, concomitant with reduced GLUT-1, increased PC protein expression and survival advantage under nutrient-depleted conditions. Prostaglandin synthase ( PTGES ) expression was inversely correlated with melanoma patient survival. Increases in PC and PTGES gene expression were observed in some patients following progression on BRAF inhibitors. Conclusions: Altogether, our data highlight heterogeneity in metabolic adaptations during acquired resistance to vemurafenib in BRAF -mutant melanoma, potentially uncovering key clinically-relevant mechanisms for combinatorial therapeutic targeting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Fig. 4 Vemurafenib-resistant cell clones exhibit decreased glycolytic metabolism and enhanced mitochondrial anaplerotic metabolism. a Resistant R6 cells produce significantly less lactateE and show a significantly lower glucose uptake in comparison to A375 cells. b R6 cells produce significantly less glutamate ([4]-[4,5] glutamate) than sensitive cells but maintain similar fumarate and acetate levels despite a lower glucose consumption rate, indicating a potential upregulation in TCA activity non-glutamine or PDH dependent. Anaplerotic TCA activity is significantly higher in R6 cells compared to the parental clone (p = 0.01). c The molecular analysis of three biological replicates from A375 and R6 cells revealed a lower GLUT-1 and GLS (KGA and GAC isoforms) expression and a higher PC expression in vemurafenib-resistant cells in comparison to sensitive cells. **p < 0.01.](https://figures.cochat.ai/paper-figures/8e52c63b837d4bc9b0d828d859d1d77a/increased-inflammatory-lipid-metabolism-and-anaplerotic-mitochondrial-activation-figure-4.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Delgado-Goñi et al. reported that increased inflammatory lipid metabolism accompanies acquired resistance to vemurafenib in BRAF-mutant melanoma cells [15].”
From Inhibition of fatty acid synthase enhances therapeutic efficacy and delays acquired resistance to BRAF-targeted therapy in colorectal cancer (2026) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“In melanoma, resistance to vemurafenib has been linked to increased mitochondrial activity and dependence on lipid metabolism [15].”
From Inhibition of fatty acid synthase enhances therapeutic efficacy and delays acquired resistance to BRAF-targeted therapy in colorectal cancer (2026) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Acquired resistance to BRAF-targeted therapy is not limited to reactivation of MAPK signaling that drives aggressive cancer phenotypes, but also involves adaptive upregulation of metabolic pathways [15,46].”
From Inhibition of fatty acid synthase enhances therapeutic efficacy and delays acquired resistance to BRAF-targeted therapy in colorectal cancer (2026) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Targeting metastasis-initiating cells through the fatty acid receptor CD36
Pascual, G., Avgustinova, A., Mejetta, S., Martín, M., Castellanos, A., Attolini, C. S.-O., Berenguer, A., Prats, N., Toll, A., Hueto, J. A., et al. (2017) · Nature · doi:10.1038/nature20791 · Cited by 1,437
Targeting cancer metabolism: a therapeutic window opens
Vander Heiden, M. G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3504 · Cited by 1,411
Lipid metabolic reprogramming in cancer cells
Beloribi-Djefaflia, S., Vasseur, S., & Guillaumond, F. (2016) · Oncogenesis · doi:10.1038/oncsis.2015.49 · Cited by 1,398
Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., Wubbenhorst, B., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,259
Cited by
Raman-guided subcellular pharmaco-metabolomics for metastatic melanoma cells
Du, J., Su, Y., Qian, C., Yuan, D., Miao, K., Lee, D., Ng, A. H. C., Wijker, R. S., Ribas, A., Levine, R. D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18376-x · Cited by 171
Geisen, M. E., Tessmann, J. W., Kelson, C. O., He, D., Wang, C., Faisal, A. S. M., Beswick, E. J., Baca, Y., Rock, S., Kolesar, J. M., et al. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101283
“…et al. showed that sustained SREBP-1-dependent lipogenesis is a key mediator of resistance to BRAF-targeted therapy in melanoma [14] and Delgado-Go ˜ ni et al. reported that increased inflammatory lipid metabolism accompanies acquired resistance to vemurafenib in BRAF-mutant melanoma cells [15].”
Influential
Metadata
- Authors
- Delgado-Goñi, T., Galobart, T. C., Wantuch, S., Normantaite, D., Leach, M. O., Whittaker, S. R., & Beloueche-Babari, M.
- Affiliations
- Royal Marsden NHS Foundation Trust (GB)
- Institute of Cancer Research (GB)
- Corresponding author
- Leach, Martin O.
- Venue
- British Journal of Cancer
- Published
- 2019-12-10
- Volume
- 122
- Issue
- 1
- Pages
- 72-81
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC6964672
- OpenAlex
- W2993997447
- Cited by
- 39
- References
- 52
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 7 · 2020: 7 · 2019: 1
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- British Journal of Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- RCUK | Medical Research Council (MR/K011057/1)
- Cancer Research UK (C1060/A10334, C1090/A16464)
- Start-up funds from The Institute of Cancer Research.
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- vemurafenib resistance, BRAF-mutant melanoma, acquired drug resistance, prostaglandin E2 synthesis, prostaglandin E synthase, pyruvate carboxylase, anaplerotic metabolism, mitochondrial metabolism, EGFR inhibition, GLUT1, metabolic vulnerability
- MeSH terms
- Prostaglandin-E Synthases, Gefitinib, Vemurafenib, Antineoplastic Agents, Cell Survival, Humans, Melanoma, Mitochondria, Mutation, Pyruvate Carboxylase, Skin Neoplasms, Dinoprostone, Signal Transduction, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Cell Line, Tumor, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells. https://app.cochat.ai/papers/10.1038/s41416-019-0628-x
- The paper
- Delgado-Goñi, T., Galobart, T. C., Wantuch, S., Normantaite, D., Leach, M. O., Whittaker, S. R., & Beloueche-Babari, M. (2020). Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells. British Journal of Cancer. https://doi.org/10.1038/s41416-019-0628-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.